Recent Quotes (30 days)

You have no recent quotes
chg | %

Portola Pharmaceuticals Inc  

(Public, NASDAQ:PTLA)   Watch this stock  
Find more results forPTLA
50.33
-0.32 (-0.63%)
Real-time:   1:26pm GMT-4
NASDAQ real-time data - Disclaimer
Currency in USD
Range 50.16 - 50.97
52 week 15.68 - 67.10
Open 50.65
Vol / Avg. 146,927.00/1.15M
Mkt cap 3,229.75M
P/E     -
Div/yield     -
EPS -4.55
Shares 57.66M
Beta 1.27
Inst. own 93%
Nov 6, 2017
Q3 2017 Portola Pharmaceuticals Inc Earnings Release (Estimated) - 4:00pm GMT-5 - Add to calendar
Sep 5, 2017
Portola Pharmaceuticals Inc Corporate Call update on Bevyxxa(�) (betrixaban) launch plans - Webcast
Aug 9, 2017
Q2 2017 Portola Pharmaceuticals Inc Earnings Call - Webcast
Aug 9, 2017
Q2 2017 Portola Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -1832.95% -755.16%
Operating margin -1738.42% -759.31%
EBITD margin - -753.89%
Return on average assets -86.15% -63.36%
Return on average equity -204.95% -87.08%
Employees 163 -
CDP Score - -

Address

270 E Grand Ave Ste 22
SOUTH SAN FRANCISCO, CA 94080-4811
United States - Map
+1-650-2446864 (Phone)
+1-650-2467376 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company's two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company's Syk is a mediator of immune response in various types of immune cells. The Company has a program of selective Syk inhibitors, one of which is partnered with Ora Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa in development for extended duration venous thromboembolism (VTE) prophylaxis in acute medically ill patients. Andexanet alfa is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor.

Officers and directors

Hollings C. Renton III IndependentChairman of the Board
Age: 70
Bio & Compensation  - Reuters
William Lis Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Mardi C. Dier Chief Financial Officer, Executive Vice President
Age: 53
Bio & Compensation  - Reuters
John T. Curnutte M.D. Ph.D. Executive Vice President - Research & Development
Age: 65
Bio & Compensation  - Reuters
Tao Fu Executive Vice President, Chief Commercial and Business officer
Age: 45
Bio & Compensation  - Reuters
Jeffrey W. Bird M.D. Ph.D. Independent Director
Age: 56
Bio & Compensation  - Reuters
Laura A. Brege Independent Director
Age: 59
Bio & Compensation  - Reuters
Dennis M. Fenton Ph.D. Independent Director
Age: 65
Bio & Compensation  - Reuters
Charles J. Homcy M.D. Independent Director
Age: 68
Bio & Compensation  - Reuters
John H. Johnson Independent Director
Age: 59
Bio & Compensation  - Reuters